REG - LungLife AI, INC - Directorate Change

LungLife AIAnnouncement

25/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241025:nRSY5520Ja&default-theme=true

RNS Number : 5520J  LungLife AI, INC  25 October 2024

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Directorate Change

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces the resignation of James McCullough, as a non-executive
director of the company, with effect from 24 October 2024.

 

James McCullough has taken the decision to step down from the Board to focus
on his Executive role at Renalytix plc.

 

Following this resignation, the Board remains confident in its current
composition, which continues to reflect a strong balance of skills,
experience, and independence. At this time, the Board has no immediate plans
to seek a replacement, as it believes the current structure, together with the
Scientific Advisory Board, is well-positioned to support the company's ongoing
growth and development and does not impact the composition and independence of
our committees.

 

Roy Davis, Non-Executive Chairman commented "On behalf of the Board I would
like to thank James for his significant contribution as Non-executive
Director to LungLife AI and wish him all the best in the future. Whilst we
will miss his insights, the Board remains strong and independent, supported by
our Scientific Advisory Board, and we are confident in our ability to continue
delivering on our long-term goals for the business."

 

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    via investors@lunglifeai.com
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Lydia Zychowska / Sara Wallace

 Goodbody (Joint Broker)                             Tel: +44 (0) 20 3841 6202
 Tom Nicholson / Cameron Duncan

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

Our Purpose is to be a driving force in the early detection to lung cancer.
And our Vision is to invert the 20:80 ratio such that in years to come at
least 80% of lung cancer is detected early.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFITISLSFIS